Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Vaccines against botulism.

Karalewitz AP, Barbieri JT.

Curr Opin Microbiol. 2012 Jun;15(3):317-24. doi: 10.1016/j.mib.2012.05.009. Epub 2012 Jun 12. Review.

PMID:
22694934
2.

Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.

Yu YZ, Liu S, Ma Y, Gong ZW, Wang S, Sun ZW.

Hum Vaccin Immunother. 2014;10(7):1874-9. doi: 10.4161/hv.28937.

3.

What next for botulism vaccine development?

Webb RP, Smith LA.

Expert Rev Vaccines. 2013 May;12(5):481-92. doi: 10.1586/erv.13.37. Review.

PMID:
23659297
4.

Enhancing the protective immune response against botulism.

Przedpelski A, Tepp WH, Kroken AR, Fu Z, Kim JJ, Johnson EA, Barbieri JT.

Infect Immun. 2013 Jul;81(7):2638-44. doi: 10.1128/IAI.00382-13. Epub 2013 May 13.

5.

Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.

Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA.

Vaccine. 2007 May 22;25(21):4273-82. Epub 2007 Mar 16.

PMID:
17395341
6.

Development of vaccines for prevention of botulism.

Byrne MP, Smith LA.

Biochimie. 2000 Sep-Oct;82(9-10):955-66. Review.

PMID:
11086225
7.

Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.

Moreira C Jr, da Cunha CE, Moreira GM, Mendonça M, Salvarani FM, Moreira ÂN, Conceição FR.

Anaerobe. 2016 Aug;40:58-62. doi: 10.1016/j.anaerobe.2016.05.012. Epub 2016 May 25.

PMID:
27236078
8.

Progress toward development of an inhalation vaccine against botulinum toxin.

Park JB, Simpson LL.

Expert Rev Vaccines. 2004 Aug;3(4):477-87. Review.

PMID:
15270652
9.

Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors.

Yu Y, Yu J, Li N, Wang S, Yu W, Sun Z.

Vaccine. 2009 Oct 19;27(44):6148-53. doi: 10.1016/j.vaccine.2009.08.022. Epub 2009 Aug 25.

PMID:
19712769
10.

Botulism and vaccines for its prevention.

Smith LA.

Vaccine. 2009 Nov 5;27 Suppl 4:D33-9. doi: 10.1016/j.vaccine.2009.08.059. Review.

PMID:
19837283
11.

Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

Baldwin MR, Tepp WH, Pier CL, Bradshaw M, Ho M, Wilson BA, Fritz RB, Johnson EA, Barbieri JT.

Infect Immun. 2005 Oct;73(10):6998-7005.

12.

Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.

Gil LA, da Cunha CE, Moreira GM, Salvarani FM, Assis RA, Lobato FC, Mendonça M, Dellagostin OA, Conceição FR.

PLoS One. 2013 Jul 31;8(7):e69692. doi: 10.1371/journal.pone.0069692. Print 2013.

13.

Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3.

Webb RP, Smith TJ, Wright P, Brown J, Smith LA.

Vaccine. 2009 Jul 16;27(33):4490-7. doi: 10.1016/j.vaccine.2009.05.030. Epub 2009 May 28.

PMID:
19450643
14.

Recombinant holotoxoid vaccine against botulism.

Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR.

Infect Immun. 2008 Jan;76(1):437-42. Epub 2007 Oct 29.

15.

Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.

Yu Y, Shi D, Liu S, Gong ZW, Wang S, Sun Z.

Hum Vaccin Immunother. 2015;11(2):468-73. doi: 10.4161/hv.29714.

16.

New targets in the search for preventive and therapeutic agents for botulism.

Anniballi F, Lonati D, Fiore A, Auricchio B, De Medici D, Locatelli CA.

Expert Rev Anti Infect Ther. 2014 Sep;12(9):1075-86. doi: 10.1586/14787210.2014.945917. Epub 2014 Aug 4. Review.

PMID:
25089560
17.

Production of recombinant botulism antigens: a review of expression systems.

Moreira GM, Cunha CE, Salvarani FM, Gonçalves LA, Pires PS, Conceição FR, Lobato FC.

Anaerobe. 2014 Aug;28:130-6. doi: 10.1016/j.anaerobe.2014.06.003. Epub 2014 Jun 12. Review.

PMID:
24930432
18.

Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.

Yu YZ, Zhang SM, Ma Y, Zhu HQ, Wang WB, Du Y, Zhou XW, Wang RL, Wang S, Yu WY, Huang PT, Sun ZW.

Clin Immunol. 2010 Nov;137(2):271-80. doi: 10.1016/j.clim.2010.07.005. Epub 2010 Aug 8.

PMID:
20696619
19.

Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E.

Mukamoto M, Maeda H, Kohda T, Nozaki C, Takahashi M, Kozaki S.

Jpn J Infect Dis. 2013;66(1):46-50.

20.

Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Henkel JS, Tepp WH, Przedpelski A, Fritz RB, Johnson EA, Barbieri JT.

Vaccine. 2011 Oct 13;29(44):7688-95. doi: 10.1016/j.vaccine.2011.07.134. Epub 2011 Aug 10.

Supplemental Content

Support Center